Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
TORONTO, June 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for Long COVID (the “Study”).
Related news for (RVVTF)
- Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
- Revive Therapeutics Advances with Next-Generation Bucillamine Development
- Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
- Revive Therapeutics Announces Proposed Shares for Debt Transaction
- Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment